Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
Total Valuation
Piramal Pharma Limited has a market cap or net worth of ₹234.48B. The enterprise value is ₹278.13B.
Market Cap₹234.48B
Enterprise Value₹278.13B
Share Statistics
Piramal Pharma Limited has 1,329,248,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,329,248,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Piramal Pharma Limited’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 0.63%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)0.63%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee13.20M
Profits Per Employee-485.10K
Employee Count6,719
Asset Turnover0.49
Inventory Turnover2.12
Valuation Ratios
The current PE Ratio of Piramal Pharma Limited is ―. Piramal Pharma Limited’s PEG ratio is 0.12.
PE Ratio―
PS Ratio2.04
PB Ratio2.22
Price to Fair Value2.22
Price to FCF35.50
Price to Operating Cash Flow24.97
PEG Ratio0.12
Income Statement
In the last 12 months, Piramal Pharma Limited had revenue of 88.69B and earned -3.26B in profits. Earnings per share was -2.46.
Revenue88.69B
Gross Profit23.83B
Operating Income903.80M
Pretax Income-1.76B
Net Income-3.26B
EBITDA9.22B
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was 8.90B and capital expenditures -4.33B, giving a free cash flow of 4.57B billion.
Operating Cash Flow8.90B
Free Cash Flow4.57B
Free Cash Flow per Share3.43
Dividends & Yields
Piramal Pharma Limited pays an annual dividend of ₹0.14, resulting in a dividend yield of 0.08%
Dividend Per Share₹0.14
Dividend Yield0.08%
Payout Ratio-46.67%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change-14.38%
50-Day Moving Average154.57
200-Day Moving Average176.17
Relative Strength Index (RSI)61.72
Average Volume (3m)264.14K
Important Dates
Piramal Pharma Limited upcoming earnings date is Aug 5, 2026, During Market Hours (Confirmed).
Last Earnings DateApr 28, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Piramal Pharma Limited as a current ratio of 1.51, with Debt / Equity ratio of 69.52%
Current Ratio1.51
Quick Ratio0.87
Debt to Market Cap0.31
Net Debt to EBITDA4.83
Interest Coverage Ratio0.27
Taxes
In the past 12 months, Piramal Pharma Limited has paid 1.50B in taxes.
Income Tax1.50B
Effective Tax Rate-0.85
Enterprise Valuation
Piramal Pharma Limited EV to EBITDA ratio is 24.46, with an EV/FCF ratio of 44.24.
EV to Sales2.54
EV to EBITDA24.46
EV to Free Cash Flow44.24
EV to Operating Cash Flow16.11
Balance Sheet
Piramal Pharma Limited has ₹7.44B in cash and marketable securities with ₹48.51B in debt, giving a net cash position of -₹41.07B billion.
Cash & Marketable Securities₹7.44B
Total Debt₹48.51B
Net Cash-₹41.07B
Net Cash Per Share-₹30.90
Tangible Book Value Per Share₹30.35
Margins
Gross margin is 45.23%, with operating margin of 1.02%, and net profit margin of -3.68%.
Gross Margin45.23%
Operating Margin1.02%
Pretax Margin-1.99%
Net Profit Margin-3.68%
EBITDA Margin10.39%
EBIT Margin1.02%
Analyst Forecast
The average price target for Piramal Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.08%
EPS Growth Forecast-458.85%